A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled Trial to Evaluate LB1148 for Post-Surgical Complications Following Cardiovascular Shock in Patients Undergoing Major Cardiovascular Surgery
Latest Information Update: 07 May 2021
At a glance
- Drugs Tranexamic acid (Primary)
- Indications Cardiogenic shock; Postoperative complications
- Focus Therapeutic Use
- 04 May 2021 Status changed from recruiting to completed, according to a Palisade Bio media release.
- 24 Mar 2020 Results presented in the Leading BioSciences Media Release.
- 24 Mar 2020 Primary endpoint (18-hour improvement in return to normal bowel function for patients treated with LB1148 as compared to placebo) has been met, according to a Leading BioSciences media release.